3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
102
Neoplasm Metastasis
13
Neoplasms
6
Triple Negative Breast Neoplasms
5
Breast Diseases
5
Neoplasms by Site
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Unilateral Breast Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms, Male
2
Breast Cancer Female
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Interventions
Fulvestrant
19
Letrozole
10
Anastrozole
8
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Injections
4
Goserelin
4
Docetaxel
4
trastuzumab deruxtecan
3
pyrotinib
3
exemestane
3
Vinorelbine
3
Aromatase Inhibitors
3
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
dalpiciclib
2
abemaciclib
2
Trastuzumab
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
abemaciclib
×
Breast
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled
NCT04227327
2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2
Terminated
31 enrolled